Research on Follistatin 344 Peptide?
Muscle Mass and Strength: By controlling myostatin, a crucial negative regulator of skeletal muscle growth, this alternatively spliced form of follistatin, FS344, has demonstrated considerable promise in increasing lean muscle mass and strength (1). FS344 demonstrates the effectiveness of myostatin inhibition by promoting muscle tissue growth and myofiber hypertrophy by blocking both myostatin and activin A through interactions with activin type II and activin type IIB receptors.
When administered via adeno-associated virus (AAV1-FS344), this therapy results in notable and long-lasting increases in muscle size and strength, according to preclinical research conducted in mice and cynomolgus macaque monkeys (2). These results highlight follistatin’s potential as a treatment for neuromuscular disorders and muscle-wasting disorders.
Importantly, FS344 avoids off-target effects, such as impacts on the hypothalamic-pituitary-gonadal axis, by secreting a peptide that circulates in the serum without binding to nonmuscle cells. Furthermore, it enhances muscle growth without interfering with growth hormone pathways. Long-term studies revealed no adverse effects on organ systems or reproductive capabilities, further supporting its safety and potential as a targeted therapeutic approach (3).
Neuromuscular Diseases: Studies have shown the potential of Follistatin 344 as a gene therapy for neuromuscular diseases, particularly sporadic inclusion body myositis (sIBM) (4). Delivered via adeno-associated virus (AAV1-FS344), it inhibits the myostatin pathway, enhancing muscle mass and strength.
In a clinical trial, sIBM patients treated with FS344 demonstrated significant improvement in the 6-minute walk test, with a median annualized gain of +56.0 m/year compared to a decline in untreated subjects (5). FS344 also reduced fibrosis and improved muscle regeneration. Research suggests it shows promise for mild to moderate neuromuscular diseases, safely avoiding hormonal side effects.
Reduced Fibrosis and Inflammation: FS344 has demonstrated potential in reducing fibrosis, a hallmark of many neuromuscular disorders. The peptide inhibits the myostatin pathway, promoting muscle regeneration and reducing fibrotic tissue accumulation.
Preclinical studies and clinical trials in conditions like sporadic inclusion body myositis (sIBM) revealed that treatment with follistatin 344 not only increased muscle mass and strength but also decreased fibrosis in affected muscles. This reduction in fibrotic tissue improves overall muscle function and highlights the peptide’s therapeutic potential (3).
Repair and Regeneration:Follistatin 344 helps muscles repair and grow by blocking myostatin and activin, which normally limit muscle growth. Research indicates that this peptide promotes satellite cell activation, a vital step in muscle growth and repair. In irradiated muscles with impaired satellite cell activity, FS344-induced hypertrophy was reduced, highlighting the role of cell proliferation (6).
Beyond growth, FS344 also improves muscle healing after injury. It does this by reducing scar tissue (fibrosis) and increasing new blood vessel formation (neovascularization). It also activates genetic factors like MyoD and myogenin, which help muscle cells develop (7). These findings suggest that Follistatin 344 could be a promising treatment for muscle injuries and diseases, such as muscular dystrophies, by enhancing muscle healing.
Metabolic Regulation: Follistatin 344 plays a significant role in metabolic regulation by modulating the transforming growth factor-β (TGF-β) signaling pathway. Studies in transgenic pigs expressing FS344 in skeletal muscle revealed increased muscle growth, reduced fat deposition, and improved metabolic profiles. The peptide influences key pathways, including PIK3–AKT signaling, calcium-mediated signaling, and amino acid metabolism, while promoting oxidative metabolism in muscle (8).
Additionally, it alters lipid metabolism, reducing lipid synthesis and storage in subcutaneous fat and enhancing lipid catabolism in retroperitoneal fat. By promoting adipose browning and mitochondrial biogenesis, FS344 shows potential as a therapeutic agent for obesity and related metabolic disorders (9).
Cancer Research: Depending on the type of cancer, FST344 exhibits dual roles by either stimulating or inhibiting tumor growth, making it a significant focus of investigation. Reverse transcription polymerase chain reaction (RT-PCR) studies on breast cancer reveal that FST expression is notably lower in cancerous tissues compared to normal tissues, with reduced levels correlating to poor survival rates and increased metastasis (10).
In mouse models, FST overexpression has been shown to inhibit lung metastases, reduce invasion, and suppress activin-induced cell migration, indicating its potential role as a metastasis suppressor (11). Conversely, FSTL1, a related protein, has been found to promote tumor growth, migration, and metastasis in esophageal squamous cell carcinoma (ESCC) by disrupting NFκB and BMP signaling pathways, highlighting its promise as a therapeutic target (12).
Buy Follistatin 344 Pre-Mixed Peptide Pen from Peptide Works for research use. Each 1 mg cartridge can be purchased separately or as part of a full kit, including a reusable pen, needle tips, and a carry case for convenient and accurate preparation.
References
(1) Haidet AM, Rizo L, Handy C, Umapathi P, Eagle A, Shilling C, Boue D, Martin PT, Sahenk Z, Mendell JR, Kaspar BK. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4318-22.
(2) Janaiah Kota, Chalonda R Handy, Amanda M Haidet, Chrystal L Montgomery, et al (2009) Follistatin gene delivery enhances muscle growth and strength in nonhuman primates – Science Translational Medicine, 2009 Nov 11, Volume 1 (Issue 6), Page 6ra15.
(3) Louise R Rodino-Klapac, Amanda M Haidet, Janaiah Kota, Chalonda Handy, et al (2009). Inhibition of Myostatin With Emphasis on Follistatin as a Therapy for Muscle Disease – Muscle Nerve, 2009 Mar, Volume 39 (Issue 3), Pages 283–296.
(4) Jerry R Mendell, Zarife Sahenk, Samiah Al-Zaidy, Louise R Rodino-Klapac, et al (2017) Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes – Molecular Therapy, 2017 Apr 5, Volume 25 (Issue 4), Pages 870-879.
(5) Louise R Rodino-Klapac, Amanda M Haidet, Janaiah Kota, Chalonda Handy, et al (2015) Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy – Journal of Neuromuscular Diseases, 2015 Sep 2, Volume 2 (Issue 3), Pages 185-192.
(6) Hélène Gilson, Olivier Schakman, Stéphanie Kalista, Pascale Lause, et al (2009) Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin – Am J Physiol Endocrinol Metab, 2009 Jul, Volume 297 (Issue 1), Pages E157-64.
(7) Jinhong Zhu, Yong Li, Aiping Lu, Burhan Gharaibeh, et al (2011) Follistatin Improves Skeletal Muscle Healing after Injury and Disease through an Interaction with Muscle Regeneration, Angiogenesis, and Fibrosis – Am J Pathol, 2011 Aug, Volume 179 (Issue 2), Pages 915–930.
(8) LONG Ke-ren, LI Xiao-kai, ZHANG Ruo-wei, GU Yi-ren, et al (2022) Transcriptomic analysis elucidates the enhanced skeletal muscle mass, reduced fat accumulation, and metabolically benign liver in human follistatin-344 transgenic pigs – Journal of Integrative Agriculture Volume 21, Issue 9, 2022, Pages 2675-2690
(9) Zabkiewicz C, Resaul J, Hargest R, Jiang WG, Ye L. Increased Expression of Follistatin in Breast Cancer Reduces Invasiveness and Clinically Correlates with Better Survival. Cancer Genomics Proteomics. 2017 Jul-Aug, Volume 14, Page 20035.
(10) Catherine Zabkiewicz 1, Jeyna Resaul 1, Rachel Hargest 1, Wen Guo Jiang, et al (2017) Increased Expression of Follistatin in Breast Cancer Reduces Invasiveness and Clinically Correlates with Better Survival – Cancer Genomics Proteomics, 2017 Jul-Aug, Volume 14 (Issue 4), Pages 241-251.
(11) Darcie D Seachrist, Steven T Sizemore, Emhonta Johnson, Fadi W Abdul-Karim, et al (2017) Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer – Breast Cancer Research, 2017 Jun 5, Volume 19 (Issue 1), Page 66.
(12) Marco Chi-Chung Lau, Kai Yu Ng, Tin Lok Wong, Man Tong, et al (2017) FSTL1 Promotes Metastasis and Chemoresistance in Esophageal Squamous Cell Carcinoma through NFκB-BMP Signaling Cross-talk – Cancer Research, 2017 Nov 1, Volume 77 (Issue 21), Pages 5886-5899.